Primary Resistance — When Immunotherapy Never Worked at All

It means the cancer grew from the beginning, without ever shrinking or settling. Doctors call this primary resistance, and it is identified at your first response scan rather than months later. It is a different problem from treatment that worked and then failed, and it usually points to a different set of next steps.

This page is written for the appointment where you are told the first scan is worse, not better. Nothing here is a recommendation — it is the map of what that conversation should cover.

Because checkpoint inhibitors do not attack cancer directly. They release a brake on immune cells that are already inside the tumour. If those immune cells were never there, or the tumour is invisible to them, releasing the brake changes nothing. That is the single most common explanation for primary resistance.

Some tumours are immunologically “cold”. They contain very few immune cells, and carry fewer mutations, so there are fewer abnormal proteins for the immune system to recognise as foreign. NCCN and ESMO materials describe this as the main reason immunotherapy is not a first choice in several cancer types.

Some cancers are driven by something immunotherapy does not address. Lung cancers driven by an EGFR mutation or an ALK rearrangement are the clearest example: NCCN and ESMO direct these towards targeted therapy rather than a single checkpoint inhibitor. Co-occurring STK11 or KEAP1 mutations in lung adenocarcinoma are also associated with less benefit.

Some of it is about the body, not the tumour. Published series associate lower benefit with liver metastases, a large volume of disease, reduced fitness, baseline steroids started for a non-cancer reason, and broad-spectrum antibiotics given close to the start. None of these withholds treatment on its own, or explains an individual case with certainty.

Often the honest answer is that nobody knows yet. No test reliably predicts non-response before treatment starts. If your oncologist says the reason is not clear in your case, that is where the evidence sits, not an evasion.

Usually not wrong, but it was never a promise. PD-L1 shifts the odds; it does not decide them. Some patients with high PD-L1 never respond, and some with low or negative PD-L1 do. A result that did not predict your outcome is a limitation of the biomarker, not proof of a laboratory error.

PD-L1 is a probability marker, not a pass or fail. NCCN and ESMO use it to identify who is more likely to benefit, not who will. The same score can sit behind two completely different outcomes.

There are real technical reasons a result can mislead. Laboratories use different antibody clones and different scoring systems, so two reports are not always comparable. PD-L1 can be patchy within one tumour, so a small core may not represent the whole of it. And expression changes over time, so an archival block taken a year or two ago may no longer describe the disease being treated today.

PD-L1 is not the only marker worth checking. Mismatch-repair status, reported as MMR proteins or microsatellite instability, and for some cancers tumour mutational burden, are separate tests that can change what is offered. Where a driver mutation such as EGFR or ALK was never tested, that gap matters more than the PD-L1 number.

Whether to repeat the test is a decision, not a routine. Repeat testing usually needs fresh tissue, which means another biopsy with its own risk, delay and cost. Ask your oncologist directly: if the result comes back different, what would we do differently? If the answer is nothing, the biopsy is unlikely to help. Ask for a written estimate before any sample is sent.

Not on its own — and palliative care is not a replacement for treatment in any case. It is symptom and quality-of-life support that runs alongside cancer treatment. You can start a different systemic treatment and see a palliative care team in the same week. ASCO and WHO both describe it as a service to introduce early.

In practice, that team works on the parts of the illness a busy oncology clinic has the least time for: pain that is not fully controlled, breathlessness, poor appetite, disturbed sleep, anxiety in patient and family, and practical planning. Adding them does not remove your oncologist and does not change your eligibility for a further line of treatment. With primary resistance the news arrives early, and families who delay the referral until symptoms are severe get crisis management instead of steady support.

• If your cancer responded first and grew later, that is acquired resistance and a different decision — Continuing Immunotherapy Beyond Progression explains when the same drug is carried on anyway.
• If some areas shrank while others grew, this is not primary resistance — Mixed Response: Some Tumours Shrinking, Others Growing covers that pattern.
• If the harder question is whether to stop rather than switch, Talking to Your Oncologist About Stopping gives you the words.
• For how immunotherapy is selected, delivered as day care and reassessed, see Immunotherapy at CION Cancer Clinics.

Facing this decision for your own family? Get a free second opinion and a medical oncologist will go through the scan, the biomarker report and the options that remain.